New immunotherapies push SCLC market in USA over $1 billion, says analyst .

Links :
*.- KHTCNHF888
*.- LBUGFCL8188

... PharmaMar’s lurbinectedin received priority review in February 2020 for the treatment of patients who progressed on previous platinum therapy based on data from a single-arm phase two study showing an overall response rate (ORR) of 35.2%. Historically, this compares favourably with Keytruda’s 19% ORR.